and receiving grant/research support from Bayer HealthCare.ĭaniel Spratt, MD, Panel Member, has disclosed receiving honorarium from Blue Earth Diagnostics, Novartis Pharmaceuticals Corporation, Pfizer Inc., and Varian Medical Systems, Inc. McKay, MD, Panel Member, has disclosed receiving consulting fees from AstraZeneca Pharmaceuticals LP, AVEO Pharmaceuticals, Inc., Bayer HealthCare, Bristol-Myers Squibb Company, Calithera Biosciences Inc., Caris Life Sciences, Dendreon Corporation, Exelixis Inc., Janssen Pharmaceutica Products, LP, Merck & Co., Inc., Myovant Sciences, Novartis Pharmaceuticals Corporation, Pfizer Inc., sanofi-aventis US, SeaGen, Sorrento Therapeutics, Inc., Telix Pharmaceuticals Limited, and Tempus Labs, Inc. and receiving consulting fees from Johnson & Johnson. receiving grant/research support from Blue Earth Diagnostics and Regeneron Pharmaceuticals, Inc. Sandy Srinivas, MD, Panel Vice Chair, has disclosed serving as a scientific advisor for Bayer HealthCare, Janssen Pharmaceutica Products, LP, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation and receiving grant/research support from Bayer HealthCare, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.īrian Chapin, MD, Panel Member, has disclosed serving as a scientific advisor for Janssen Pharmaceutica Products, LP, Merck & Co., Inc., and Pfizer Inc. Schaeffer, MD, PhD, Panel Chair, has disclosed serving as a scientific advisor for AbbVie, Inc., Astellas Pharma US, Inc., Janssen Scientific Affairs, LLC, Lantheus, and Pfizer, Inc. All of the relevant financial relationships listed for these individuals have been mitigated.Įdward M.
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose.
Shead, MS, Senior Director, Patient Information Operations, NCCN Freedman-Cass, PhD, Manager, Guidelines Processes, NCCNĭorothy A. Berardi, MSc, Guidelines Layout Specialist, NCCNĭeborah A. The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose. Individuals Who Provided Content Development and/or Authorship Assistance: If you have any questions, please email date: DecemExpiration date: December 10, 2023 Your credit cannot be reported without this information. Before completing these requirements, be sure your NCCN profile has been updated with your NAPB e-profile ID and date of birth. Continuing pharmacy education credit is reported to the CPE Monitor once you have completed the posttest and evaluation and claimed your credits. Pharmacists: You must complete the posttest and evaluation within 30 days of the activity. To participate in this journal CE activity: (1) review the educational content (2) take the posttest with a 66% minimum passing score and complete the evaluation at and (3) view/print certificate. PAs should only claim credit commensurate with the extent of their participation.Īll clinicians completing this activity will be issued a certificate of participation. Approval is valid until December 10, 2023. This activity is designated for 1.0 AAPA Category 1 CME credit. Physician Assistants: NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. Pharmacists: NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. Nurses: NCCN designates this educational activity for a maximum of 1.0 contact hour. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians: NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
0 kommentar(er)
